Watch: Hampden under-19 women's coach Chris Meade after interleague win against Ballarat China sees Trump's new law as 'one ...

Tony Abbott has serious concerns with the Japanese bid for defence contract Russia launches largest drone and missile attack ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Ginger also understands what it means to be a visible figure in the body-diverse community. Should she win All Stars 10, ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...